The most common adverse reactions were diarrhea, paronychia and skin cracks (30% each), and no grade 3 or higher AEs were observed.[26] A multicenter phase Ib clinical study (NCT04958967) is evaluating the efficacy and safety of furmonertinib at different doses (160 mg/day and 240 mg/day) in patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutation.[27] Of note, there are also 2 ongoing clinical trials (EXCLAIM-2 and PAPILLON) for first-line treatment of patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutation. This evidence concerns the gene EGFR and paronychia.